<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623466</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-CL21</org_study_id>
    <nct_id>NCT01623466</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches</brief_title>
  <acronym>ATI-CL21</acronym>
  <official_title>A Randomized, Open-Label, Parallel Group Study To Evaluate Pharmacokinetic Profile, Wearability And Safety of Two Progestin-Only Patches Containing Different Doses Of Levonorgestrel (LNG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics, safety and wearability in two size patches of AG890 over eight weeks will
      be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate pharmacokinetic (PK) profile, patch wearability (adhesion and skin irritation),
      and safety of AG890-6.5 and AG890-12.5 TCDS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levonorgestrel Pharmacokinetic Profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Patch Adhesion</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale:
0: ≥90% adhered (no lift)
≥75% adhered but &lt;90% (some edges showing lift)
≥50% adhered but &lt;75% (half of system lifts off)
&lt;50% (&lt; half of system lifts off, but undetached)
patch completely detached</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Irritation at Patch Application Site</measure>
    <time_frame>8 weeks</time_frame>
    <description>Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale:
0: None
Mild
Moderate
Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Itching at Patch Application Site</measure>
    <time_frame>8 weeks</time_frame>
    <description>Self-reported worst skin itching at patch application site by subject using a 4-point scale:
0. None
Mild
Moderate
Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cycle Control</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement of unscheduled bleeding/spotting days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AG890-6.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate levonorgestrel delivery in AG890-6.5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG890-12.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate levonorgestrel delivery in AG890-12.5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel</intervention_name>
    <description>transdermal contraceptive delivery system</description>
    <arm_group_label>AG890-6.5</arm_group_label>
    <arm_group_label>AG890-12.5</arm_group_label>
    <other_name>patch, transdermal contraceptive delivery system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) greater than or equal to 18.

          -  Willing to use a non-hormonal method of contraception if of childbearing potential, or
             have already undergone previous bilateral tubal ligation or hysterectomy

          -  Willing to refrain from excessive use of alcohol from 48 hours prior to patch
             application through completion of the study.

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Lactating women

          -  Status post-partum or post-abortion within a period of 2 months prior to the start of
             study medication

          -  A cervical cytology smear of Papanicolaou (Pap) class III or greater or a Bethesda
             System report of low grade squamous intraepithelial lesions (SIL) or greater

          -  Smoking

          -  Hypertension (blood pressure &gt;140 mm Hg systolic and/or &gt;90 mm Hg diastolic)

          -  Valvular heart disease with complications

          -  ECG (in women with BMI ≥35 kg/m2) with clinically significant findings

          -  Diabetes Mellitus

          -  History of headaches with focal neurological symptoms

          -  Uncontrolled thyroid disorder

          -  Sickle cell anemia

          -  Current or history of clinically significant depression in the last year

          -  Known disturbance of lipid metabolism

          -  Acute or chronic hepatocellular disease with abnormal liver function

          -  Hepatic adenoma or carcinoma

          -  Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use

          -  Plans for major surgery

          -  History of or existing venous and arterial thrombotic and thromboembolic disorder,
             vascular disease, cerebral vascular, or coronary artery disease

          -  Undiagnosed abnormal genital bleeding

          -  Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent
             neoplasia

          -  History or presence of dermal hypersensitivity in response to topical applications
             (bandages, surgical tape, etc.)

          -  Use of an injectable hormonal contraceptive within the past 10 months prior to the
             screening visit

          -  Use of a contraceptive implant or hormone-medicated intrauterine device (IUD) within 1
             month prior to the screening visit

          -  Use of oral contraceptives or other sex steroid hormones within 2 months prior to the
             screening visit

          -  Chronic use of any medication that might interfere with the efficacy of hormone
             contraceptives (including barbiturates, bosentan, carbamazepine, felbamate,
             griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate, and HIV
             protease inhibitors), OR use of these medications within the past 3 months prior to
             screening visit

          -  A recent history (within prior 2 years ) of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Garner, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Agile Therapeutics</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <results_first_submitted>July 26, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2017</results_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK and Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AG890-6.5</title>
          <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
        </group>
        <group group_id="P2">
          <title>AG890-12.5</title>
          <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>AG890-6.5</title>
          <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
        </group>
        <group group_id="B2">
          <title>AG890-12.5</title>
          <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.83" spread="8.473"/>
                    <measurement group_id="B2" value="34.94" spread="6.673"/>
                    <measurement group_id="B3" value="32.39" spread="7.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levonorgestrel Pharmacokinetic Profile</title>
        <description>The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.</description>
        <time_frame>8 weeks</time_frame>
        <population>Primary PK population</population>
        <group_list>
          <group group_id="O1">
            <title>AG890-6.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
          <group group_id="O2">
            <title>AG890-12.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Levonorgestrel Pharmacokinetic Profile</title>
          <description>The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.</description>
          <population>Primary PK population</population>
          <units>% of subjects below 175 pg/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Patch Adhesion</title>
        <description>Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale:
0: ≥90% adhered (no lift)
≥75% adhered but &lt;90% (some edges showing lift)
≥50% adhered but &lt;75% (half of system lifts off)
&lt;50% (&lt; half of system lifts off, but undetached)
patch completely detached</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>AG890-6.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
          <group group_id="O2">
            <title>AG890-12.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Patch Adhesion</title>
          <description>Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale:
0: ≥90% adhered (no lift)
≥75% adhered but &lt;90% (some edges showing lift)
≥50% adhered but &lt;75% (half of system lifts off)
&lt;50% (&lt; half of system lifts off, but undetached)
patch completely detached</description>
          <population>Safety population</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="1.004"/>
                    <measurement group_id="O2" value="0.78" spread="1.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Irritation at Patch Application Site</title>
        <description>Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale:
0: None
Mild
Moderate
Severe</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>AG890-6.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
          <group group_id="O2">
            <title>AG890-12.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Irritation at Patch Application Site</title>
          <description>Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale:
0: None
Mild
Moderate
Severe</description>
          <population>Safety population</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.471"/>
                    <measurement group_id="O2" value="0.06" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Itching at Patch Application Site</title>
        <description>Self-reported worst skin itching at patch application site by subject using a 4-point scale:
0. None
Mild
Moderate
Severe</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>AG890-6.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
          <group group_id="O2">
            <title>AG890-12.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Itching at Patch Application Site</title>
          <description>Self-reported worst skin itching at patch application site by subject using a 4-point scale:
0. None
Mild
Moderate
Severe</description>
          <population>Safety Population</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.594"/>
                    <measurement group_id="O2" value="0.39" spread="0.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cycle Control</title>
        <description>Measurement of unscheduled bleeding/spotting days.</description>
        <time_frame>8 weeks</time_frame>
        <population>Completed subjects</population>
        <group_list>
          <group group_id="O1">
            <title>AG890-6.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
          <group group_id="O2">
            <title>AG890-12.5</title>
            <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Cycle Control</title>
          <description>Measurement of unscheduled bleeding/spotting days.</description>
          <population>Completed subjects</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="4.81"/>
                    <measurement group_id="O2" value="8.3" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AG890-6.5</title>
          <description>Evaluate levonorgestrel delivery in AG890-6.5
levonorgestrel: transdermal contraceptive delivery system</description>
        </group>
        <group group_id="E2">
          <title>AG890-12.5</title>
          <description>Evaluate levonorgestrel delivery in AG890-12.5
levonorgestrel: transdermal contraceptive delivery system</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system ad breast disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publications must be reviewed and approved by sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Flood</name_or_title>
      <organization>Agile Therapeutics</organization>
      <phone>609-683-1880</phone>
      <email>lflood@agiletherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

